RAHMANI ELHAM1, AHMADI SHAHNAZ2,*, MOTAMED NILOOFAR3, GHASEMI AFSANEH4, ZAMANI ZOHREH5
1Associate Professor, Department of Gynecologic Obstetric, Bushehr University of Medical Science, Bushehr, Iran - 2Associate Professor, Department of Gynecologic Obstetric, Iran University of Medical Sciences, Tehran, Iran - 3Associate Professor, Associate pro- fessor of Community, Bushehr University of Medical Sciences, Bushehr, Iran - 4Associate Professor, Department of Gynecologic Obstetric, Iran University of Medical Sciences, Tehran, Iran - 5Medical Student, Bushehr University of Medical Science, Bushehr, Iran
Background: Aim of this study is to compare the short-term effect of GnRH antagonist in follicular phase with fixed protocol of GnRH antagonist in IVF cycles in infertile women.
Materials and methods: The present study was conducted on 60 patients. Patients were divided into two groups of 30, based on random table of Excel. The target group received 0.25 mg per day subcutaneous Cetrorelix on days 1, 2 and 3, which was injected on the fourth day of menstruation and for the control group, fixed Cetrorelix, was started on the 6th day of cycle and continued until HCG injection. Both groups received 300 IU gonadotropin for four days that was adjusted based on the ultrasound results. Then gonadotropin consumption, number of oocytes and pregnancy rates were clinically compared.
Results: In the present study, there was no difference between the case and control group regarding pregnancy rate (P value = 0.54). Cetrorelix dose used and the total number of days of treatment were significantly different between the two groups (P value = 0.0001) and the target group used higher dose of Cetrorelix but had a lower duration of therapy. The two groups were not significan- tly different in the primary outcome, including chemical and clinical pregnancy (P value = 0.58) (P value = 0.68).
Conclusion: It was demonstrated in the present study that short-term and fixed use of GnRH antagonist in the follicular phase was not different and the short-term protocol decreases the length of treatment and increases the costs.
infertility, IVF, gonadotropins, follicular phase